Gain Therapeutics, Inc.

Gain Therapeutics is a clinical-stage biotechnology company that utilizes its computational discovery platform, Magellan, to identify novel allosteric binding sites on disease-causing proteins. The company focuses on developing small molecule therapeutics, known as structurally targeted allosteric regulators, to treat conditions associated with protein misfolding and dysfunction. Its research and pipeline target central nervous system disorders, lysosomal storage disorders, metabolic diseases, and oncology indications. The company's lead drug candidate, GT-02287, is being developed for the treatment of Parkinson's disease with or without GBA1 mutations. Gain Therapeutics advances its programs and targets through collaborations with academic research institutions and industry licensing or co-development partners.

The company operates at a clinical stage, conducting Phase 1 clinical studies in healthy volunteers and patients with Parkinson's disease in Australia. In addition, its intellectual property portfolio includes granted patents across the United States, Europe, Japan, China, and Canada. The provided text does not disclose the location of the company's headquarters.

Summary of the business section of Gain Therapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 20 full-time employees and one part-time employee.”